News
PFE
29.44
-0.47%
-0.14
Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?
The Motley Fool · 8h ago
Novavax Inc. Stock Slides 4.0%, Underperforms Peers
Dow Jones · 9h ago
Moderna Inc. Stock Advances 4.1%, Outperforms Peers
Dow Jones · 9h ago
Swiss Pharma Giant Roche Suspends German Capital Commitments Amid Dispute Over Drug Discounts
Benzinga · 12h ago
Pfizer’s Elranatamab Trial Update: What MAGNETISMM-3 Means for PFE Investors
TipRanks · 13h ago
Roche pauses German investments over healthcare reforms
Seeking Alpha · 14h ago
Intercontinental Exchange's NYSE extends trading hours for NYSE American options
Seeking Alpha · 17h ago
Weekly Report: what happened at PFE last week (1012-1016)?
Weekly Report · 20h ago
Pfizer (PFE) Stock Looks Richly Priced On Current Earnings
Simply Wall St · 1d ago
Warren Buffett's Market Warning Is Hard to Ignore. But I'd Buy These 3 Stocks Anyway.
The Motley Fool · 1d ago
Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a Year
The Motley Fool · 1d ago
Pfizer (PFE) Gets a Hold from Wells Fargo
TipRanks · 1d ago
Does Expanded Tukysa Approval Change The Bull Case For Pfizer (PFE)?
Simply Wall St · 2d ago
Pfizer Shuts One Trial, Bets Big on New Vaccine
TipRanks · 2d ago
JD Vance Touts TrumpRx Drug Price Push, Trump Accounts as ‘Economic Nationalism’ Wins Ahead Of Midterms
Benzinga · 2d ago
RBC Capital Reaffirms Their Hold Rating on Pfizer (PFE)
TipRanks · 3d ago
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends
The Motley Fool · 3d ago
Inovio Pharmaceuticals Inc. Stock Falls 4.8%, Underperforms Peers
Dow Jones · 3d ago
Novavax Inc. Stock Slides 12.2%, Underperforms Peers
Dow Jones · 3d ago
Moderna Inc. Stock Slides 7.8%, Underperforms Peers
Dow Jones · 3d ago
More
Webull provides a variety of real-time PFE stock news. You can receive the latest news about Pfizer through multiple platforms. This information may help you make smarter investment decisions.
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.